城市学术HIV诊所中长效注射卡博特韦/利匹韦林的适用性与启动因素
该回顾性队列研究纳入657名HIV感染者,评估长效注射卡博特韦/利匹韦林的适用性、启动相关因素及处方模式。63%符合条件,其中15%在获批后2.5年内启动;年轻年龄是唯一启动相关因素,且不同处方者启动率差异显著。
要点
- 63%的HIV感染者符合长效注射卡博特韦/利匹韦林条件。
- 符合条件者中仅15%启动治疗,年轻年龄与启动相关。
- 处方者间启动率差异大(0%-33%),需关注处方模式。
核心结论
- 在城市HIV诊所中,63%的HIV感染者符合长效注射卡博特韦/利匹韦林条件,获批后2.5年内15%启动。
- 年轻年龄和处方者模式显著影响长效注射卡博特韦/利匹韦林的启动。
研究设计与样本
- 回顾性队列分析,纳入美国芝加哥大学HIV诊所2021年1月1日至2023年5月31日的657名HIV感染者。
主要发现
- 657名HIV感染者中413名(63%)符合长效注射卡博特韦/利匹韦林条件。
- 符合条件者中64名(15%)启动了长效注射卡博特韦/利匹韦林。
- 多变量分析显示,年轻年龄是启动的唯一相关因素[OR 0.96, 95% CI (0.94, 0.99), P = 0.01]。
- 13名处方者的启动率从0%到33%不等(P < 0.001),2名处方者覆盖40%符合条件患者并负责70%的启动。
关键数值与推荐
- 长效注射卡博特韦/利匹韦林适用标准包括:HIV-1 RNA <50 copies/mL持续≥3个月、无活动性乙肝、无利匹韦林或卡博特韦耐药、无治疗失败史。
临床怎么用
- 应评估HIV感染者对长效注射卡博特韦/利匹韦林的适用性,并关注年轻患者及处方者差异对启动的影响。
局限性
- 单中心回顾性研究,结果可能受当地患者构成和处方习惯影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to assess eligibility for long-acting injectable (LAI) cabotegravir/rilpivirine among people with HIV (PWH), identify factors associated with initiation and examine provider prescribing patterns in an urban academic clinic in the USA. PATIENTS AND METHODS: We conducted a retrospective cohort analysis among PWH at the University of Chicago HIV clinic from 1 January 2021 to 31 May 2023. Eligibility criteria for LAI cabotegravir/rilpivirine included HIV-1 RNA <50 copies/mL for ≥3 months, no active hepatitis B, no resistance to rilpivirine or cabotegravir and no treatment failure history. Logistic regression identified factors associated with initiation among eligible PWH as well as prescribing patterns of providers. RESULTS: Of 657 PWH, 413 (63%) were eligible for LAI cabotegravir/rilpivirine. Median age was 45, 33% were women, 84% Black, 70% had permanent housing, 52% employed, 56% on Medicaid, 9% had active substance use and 26% had psychiatric comorbidities. Among those eligible, 64 PWH (15%) initiated LAI cabotegravir/rilpivirine. In multivariate analysis, younger age was the only factor associated with LAI cabotegravir/rilpivirine initiation [OR 0.96, 95% CI (0.94, 0.99), P = 0.01]. Prescribing patterns varied widely among the 13 providers, with initiation rates ranging from 0% to 33% (P < 0.001). Two providers, covering 40% of eligible patients, were responsible for 70% of initiations. CONCLUSIONS: In our urban HIV clinic, 63% of PWH were eligible for LAI cabotegravir/rilpivirine, and 15% initiated it within 2.5 years post-approval. Age and provider patterns significantly influenced LAI cabotegravir/rilpivirine uptake. Understanding factors driving LAI cabotegravir/rilpivirine uptake is key to expanding its reach.
引用
- Liegeon G, Friedman E, Kaperak C, et al. Eligibility and factors associated with long-acting injectable cabotegravir-rilpivirine initiation in an urban academic HIV clinic. J Antimicrob Chemother. 2025. PMID: 40981754. doi:10.1093/jac/dkaf346
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。